UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sperm Proteome Maturation in the Mouse Epididymis

PloS one, 2015-11, Vol.10 (11), p.e0140650-e0140650

2015

Volltextzugriff (PDF)

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A781-A781

2023

Volltextzugriff (PDF)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e5193345-n/a

2023

Volltextzugriff (PDF)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1

HemaSphere, 2023-08, Vol.7 (S3), p.e646904e-n/a

2023

Volltextzugriff (PDF)

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.726-726

2021

Volltextzugriff (PDF)

Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment

Leukemia research, 2021-12, Vol.111, p.106687-106687, Article 106687

2021

Volltextzugriff (PDF)

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Blood, 2023-11, Vol.142 (Supplement 1), p.1941-1941

2023

Volltextzugriff (PDF)

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Blood, 2017-12, Vol.130, p.5378-5378

2017

Volltextzugriff (PDF)

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3377-3377

2023

Volltextzugriff (PDF)

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.455-455

2023

Volltextzugriff (PDF)

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1933-1933

2023

Volltextzugriff (PDF)

NSP-04 Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S315-S315

2023

Volltextzugriff (PDF)

Identification and characterization of the zebra finch (Taeniopygia guttata) sperm proteome

Journal of proteomics, 2018

2018

Volltextzugriff (PDF)

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Clinical cancer research, 2024-07, Vol.30 (14), p.3006-3022

2024

Volltextzugriff (PDF)

Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8020-8020

2023

Volltextzugriff (PDF)

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.1805-1805

2019

Volltextzugriff (PDF)

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Blood, 2019-11, Vol.134 (Supplement_1), p.1782-1782

2019

Volltextzugriff (PDF)

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Blood, 2019-11, Vol.134 (Supplement_1), p.858-858

2019

Volltextzugriff (PDF)

P-228 The Detection of PR Minor Clones at Single Cell Level Identifies High Risk Disease in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S169-S169

2024

Volltextzugriff (PDF)

Abstract 839: Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.839-839

2019

Volltextzugriff (PDF)

Proteomic discovery of diverse immunity molecules in mammalian spermatozoa

Systems biology in reproductive medicine, 2012-08, Vol.58 (4), p.218-228

2012

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

ThemaBiochemical Research Methods

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(36)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Sperm Proteome Maturation in the Mouse Epididymis

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

CD33 Is Expressed in a Significant Subset of Multiple Myeloma Patients in the US and May Represent a Viable Therapeutic Target

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

NSP-04 Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 study

Identification and characterization of the zebra finch (Taeniopygia guttata) sperm proteome

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

P-228 The Detection of PR Minor Clones at Single Cell Level Identifies High Risk Disease in Multiple Myeloma

Abstract 839: Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Proteomic discovery of diverse immunity molecules in mammalian spermatozoa

Aktive Filter

Suchergebnisse filtern